Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Prior Bypass Surgery

Michael Megaly; Bishoy Abraham; Ashish Pershad; Stéphane Rinfret; Khaldoon Alaswad; Santiago Garcia; Lorenzo Azzalini; Anthony Gershlick; M. Nicholas Burke; Emmanouil S. Brilakis

doi:10.1016/j.jcin.2019.11.033

Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Prior Bypass Surgery

Michael Megaly, Bishoy Abraham, Ashish Pershad, Stéphane Rinfret, Khaldoon Alaswad, Santiago Garcia, Lorenzo Azzalini, Anthony Gershlick, M. Nicholas Burke, Emmanouil S. Brilakis

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Letter › peer-review

16 Scopus citations

Original language	English
Pages (from-to)	900-902
Number of pages	3
Journal	JACC: Cardiovascular Interventions
Volume	13
Issue number	7
DOIs	https://doi.org/10.1016/j.jcin.2019.11.033
State	Published - 13 Apr 2020

Access to Document

10.1016/j.jcin.2019.11.033

Cite this

@article{6a2bee15e8124074955844a216809ee5,

title = "Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Prior Bypass Surgery",

author = "Michael Megaly and Bishoy Abraham and Ashish Pershad and St{\'e}phane Rinfret and Khaldoon Alaswad and Santiago Garcia and Lorenzo Azzalini and Anthony Gershlick and Burke, {M. Nicholas} and Brilakis, {Emmanouil S.}",

note = "Funding Information: Please note: Dr. Rinfret has been a consultant, proctor, or speaker for Boston Scientific, Abiomed, Abbott Vascular, and Soundbite Medical; and has received research support from Soundbite Medical. Dr. Alaswad has been a consultant for Boston Scientific, Abiomed. Abbott Vascular, Cardiovascular Systems Inc., and LivaNova. Dr. Garcia has been a consultant for Surmodics, Osprey Medical, Medtronic, Edwards Lifesciences, and Abbott; and has received grant support from Edwards Lifesciences, Boston Scientific, and the VA Office of Research and Development. Dr. Azzalini has received honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies; and research support from ACIST Medical Systems, Guerbet, and Terumo. Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific; and is a shareholder in MHI Ventures and Egg Medical. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), Cardiovascular Systems Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder in MHI Ventures. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: Dr. Rinfret has been a consultant, proctor, or speaker for Boston Scientific, Abiomed, Abbott Vascular, and Soundbite Medical; and has received research support from Soundbite Medical. Dr. Alaswad has been a consultant for Boston Scientific, Abiomed. Abbott Vascular, Cardiovascular Systems Inc., and LivaNova. Dr. Garcia has been a consultant for Surmodics, Osprey Medical, Medtronic, Edwards Lifesciences, and Abbott; and has received grant support from Edwards Lifesciences, Boston Scientific, and the VA Office of Research and Development. Dr. Azzalini has received honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies; and research support from ACIST Medical Systems, Guerbet, and Terumo. Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific; and is a shareholder in MHI Ventures and Egg Medical. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), Cardiovascular Systems Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder in MHI Ventures. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",

year = "2020",

month = apr,

day = "13",

doi = "10.1016/j.jcin.2019.11.033",

language = "English",

volume = "13",

pages = "900--902",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Prior Bypass Surgery

AU - Megaly, Michael

AU - Abraham, Bishoy

AU - Pershad, Ashish

AU - Rinfret, Stéphane

AU - Alaswad, Khaldoon

AU - Garcia, Santiago

AU - Azzalini, Lorenzo

AU - Gershlick, Anthony

AU - Burke, M. Nicholas

AU - Brilakis, Emmanouil S.

N1 - Funding Information: Please note: Dr. Rinfret has been a consultant, proctor, or speaker for Boston Scientific, Abiomed, Abbott Vascular, and Soundbite Medical; and has received research support from Soundbite Medical. Dr. Alaswad has been a consultant for Boston Scientific, Abiomed. Abbott Vascular, Cardiovascular Systems Inc., and LivaNova. Dr. Garcia has been a consultant for Surmodics, Osprey Medical, Medtronic, Edwards Lifesciences, and Abbott; and has received grant support from Edwards Lifesciences, Boston Scientific, and the VA Office of Research and Development. Dr. Azzalini has received honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies; and research support from ACIST Medical Systems, Guerbet, and Terumo. Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific; and is a shareholder in MHI Ventures and Egg Medical. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), Cardiovascular Systems Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder in MHI Ventures. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Please note: Dr. Rinfret has been a consultant, proctor, or speaker for Boston Scientific, Abiomed, Abbott Vascular, and Soundbite Medical; and has received research support from Soundbite Medical. Dr. Alaswad has been a consultant for Boston Scientific, Abiomed. Abbott Vascular, Cardiovascular Systems Inc., and LivaNova. Dr. Garcia has been a consultant for Surmodics, Osprey Medical, Medtronic, Edwards Lifesciences, and Abbott; and has received grant support from Edwards Lifesciences, Boston Scientific, and the VA Office of Research and Development. Dr. Azzalini has received honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies; and research support from ACIST Medical Systems, Guerbet, and Terumo. Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific; and is a shareholder in MHI Ventures and Egg Medical. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (board of directors), Cardiovascular Systems Inc., Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; has received research support from Regeneron and Siemens; and is a shareholder in MHI Ventures. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2020/4/13

Y1 - 2020/4/13

UR - http://www.scopus.com/inward/record.url?scp=85082605929&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2019.11.033

DO - 10.1016/j.jcin.2019.11.033

M3 - Letter

C2 - 32192982

AN - SCOPUS:85082605929

SN - 1936-8798

VL - 13

SP - 900

EP - 902

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 7

ER -